HUP0202367A2 - FAP-aktivált tumorellenes peptidek, eljárás előállításukra, azokat tartalmazó gyógyszerkészítmények és alkalmazásuk - Google Patents
FAP-aktivált tumorellenes peptidek, eljárás előállításukra, azokat tartalmazó gyógyszerkészítmények és alkalmazásukInfo
- Publication number
- HUP0202367A2 HUP0202367A2 HU0202367A HUP0202367A HUP0202367A2 HU P0202367 A2 HUP0202367 A2 HU P0202367A2 HU 0202367 A HU0202367 A HU 0202367A HU P0202367 A HUP0202367 A HU P0202367A HU P0202367 A2 HUP0202367 A2 HU P0202367A2
- Authority
- HU
- Hungary
- Prior art keywords
- group
- amino
- fap
- pharmaceutical compositions
- groups
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title abstract 2
- 230000000259 anti-tumor effect Effects 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 125000003277 amino group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 230000000903 blocking effect Effects 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 239000000824 cytostatic agent Substances 0.000 abstract 1
- 230000001085 cytostatic effect Effects 0.000 abstract 1
- 231100000433 cytotoxic Toxicity 0.000 abstract 1
- 230000001472 cytotoxic effect Effects 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 125000004434 sulfur atom Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
- A61K47/67—Enzyme prodrug therapy, e.g. gene directed enzyme drug therapy [GDEPT] or VDEPT
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/24—Condensed ring systems having three or more rings
- C07H15/252—Naphthacene radicals, e.g. daunomycins, adriamycins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1019—Tetrapeptides with the first amino acid being basic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Nanotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Crystallography & Structural Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
kPage=A;BrkToNext=N;>(57) A találmány tárgyát az általános képletűvegyületek - ahol R1 amino-alkanoil- vagy oligopeptidoil-csoport,amelynek amino-terminális aminocsoportjához adott esetben egy blokkolócsoport kapcsolódik; Ra és Rb a kettőjük közötti N-C csoporttal együttegy adott esetben szubsztituált és adott esetben benzo- vagyciclohexanocsoporttal kondenzált heterogyűrűt képez, amelyben egy vagykét metiléncsoportot adott esetben -NH-csoport, oxigén- vagy kénatomhelyettesít; R9 hidrogénatom, alkil-, cikloalkil-, aril- vagyheteoaril-csoport; és Cyt' egy citotoxikus vagy citosztatikus vegyületmaradéka; azzal a fenntartással, hogy a háromnál több aminosavegységettartalmazó oligopeptidoilcsoportokban a Gln-csoport közvetlenül csak aSer-től eltérő csoportokhoz kapcsolódhat - és előállításuk, továbbátumorok kezelésére szolgáló gyógyszerkészítményekben prodrugként valóalkalmazásuk képezi. Ó
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13413699P | 1999-05-14 | 1999-05-14 |
Publications (2)
Publication Number | Publication Date |
---|---|
HUP0202367A2 true HUP0202367A2 (hu) | 2002-11-28 |
HUP0202367A3 HUP0202367A3 (en) | 2003-10-28 |
Family
ID=22461925
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0202367A HUP0202367A3 (en) | 1999-05-14 | 2000-05-11 | Fap-activated anti-tumor peptides, process for their preparation pharmaceutical compositions comprising thereof and their use |
Country Status (28)
Country | Link |
---|---|
US (1) | US6613879B1 (hu) |
EP (1) | EP1180116A2 (hu) |
JP (1) | JP3607201B2 (hu) |
KR (1) | KR20020030270A (hu) |
CN (1) | CN1213058C (hu) |
AR (1) | AR033792A1 (hu) |
AU (1) | AU777521B2 (hu) |
BG (1) | BG106096A (hu) |
BR (1) | BR0010564A (hu) |
CA (1) | CA2369933A1 (hu) |
CO (1) | CO5170516A1 (hu) |
CZ (1) | CZ20014097A3 (hu) |
EA (1) | EA005204B1 (hu) |
EE (1) | EE200100600A (hu) |
HK (1) | HK1048642B (hu) |
HU (1) | HUP0202367A3 (hu) |
IL (1) | IL145798A0 (hu) |
MX (1) | MXPA01011401A (hu) |
MY (1) | MY125939A (hu) |
NO (1) | NO20015536L (hu) |
NZ (1) | NZ516075A (hu) |
PL (1) | PL351680A1 (hu) |
SK (1) | SK16452001A3 (hu) |
TW (1) | TWI248444B (hu) |
UA (1) | UA73506C2 (hu) |
WO (1) | WO2000071571A2 (hu) |
YU (1) | YU80901A (hu) |
ZA (1) | ZA200109151B (hu) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MXPA02009019A (es) | 2000-03-15 | 2003-02-12 | Du Pont Pharm Co | Farmacos antineoplasticos de objetivo, que se desdoblan por la peptidasa y su uso terapeutico. |
GB0027551D0 (en) * | 2000-11-10 | 2000-12-27 | Boehringer Ingelheim Pharma | Anti-tumor compounds |
GB0027552D0 (en) * | 2000-11-10 | 2000-12-27 | Boehringer Ingelheim Pharma | Anti-tumor compounds |
JP4109123B2 (ja) * | 2001-05-09 | 2008-07-02 | セルメド オンコロジー (ユーエスエイ), インコーポレイテッド | ペプチドデホルミラーゼ活性化プロドラッグ |
US7091186B2 (en) * | 2001-09-24 | 2006-08-15 | Seattle Genetics, Inc. | p-Amidobenzylethers in drug delivery agents |
EP1333033A1 (en) * | 2002-01-30 | 2003-08-06 | Boehringer Ingelheim Pharma GmbH & Co.KG | FAP-activated anti-tumor compounds |
US20030211979A1 (en) * | 2002-01-30 | 2003-11-13 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | FAP-activated anti-tumor compounds |
CA2482029A1 (en) * | 2002-04-18 | 2003-10-30 | Maria V. Sergeeva | Peptide deformylase activated prodrugs |
US20040033957A1 (en) * | 2002-05-10 | 2004-02-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | FAP-activated anti-tumor prodrugs |
AU2003233238A1 (en) * | 2002-05-10 | 2003-11-11 | Boehringer Ingelheim Pharma Gmbh And Co Kg | Fap-activated anti-tumor prodrugs |
US20040001801A1 (en) * | 2002-05-23 | 2004-01-01 | Corvas International, Inc. | Conjugates activated by cell surface proteases and therapeutic uses thereof |
BR0315537A (pt) * | 2002-11-14 | 2005-09-27 | Celmed Oncology Usa Inc | Pró-drogas ativadas por peptìdeo desformilase |
GB0310593D0 (en) * | 2003-05-08 | 2003-06-11 | Leuven K U Res & Dev | Peptidic prodrugs |
EP1625122A1 (en) | 2003-05-14 | 2006-02-15 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
US7169926B1 (en) | 2003-08-13 | 2007-01-30 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US7678909B1 (en) | 2003-08-13 | 2010-03-16 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US7732446B1 (en) | 2004-03-11 | 2010-06-08 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US7687638B2 (en) | 2004-06-04 | 2010-03-30 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
WO2006019965A2 (en) | 2004-07-16 | 2006-02-23 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
WO2006073167A1 (ja) * | 2005-01-07 | 2006-07-13 | Ono Pharmaceutical Co., Ltd. | ピロリジン誘導体 |
AU2006246719A1 (en) * | 2005-05-19 | 2006-11-23 | Genentech, Inc. | Fibroblast activation protein inhibitor compounds and methods |
US8067248B2 (en) * | 2005-12-14 | 2011-11-29 | Luwig Institute for Cancer Research | Method for diagnosing rheumatoid arthritis via assaying myofibroblast-like synoviocytes for fibroblast activation protein |
US20100047170A1 (en) * | 2006-01-05 | 2010-02-25 | Denmeade Samuel R | Peptide Prodrugs |
WO2007112347A1 (en) | 2006-03-28 | 2007-10-04 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
WO2008005479A2 (en) * | 2006-07-06 | 2008-01-10 | University Of Wyoming | Charge reversible polymers |
WO2008116053A2 (en) * | 2007-03-20 | 2008-09-25 | Trustees Of Tufts College | Fap-activated chemotherapeutic compounds, and methods of use thereof |
ES2571217T3 (es) * | 2008-09-12 | 2016-05-24 | Cadila Pharmaceuticals Ltd | Profármacos de sitagliptina |
US9062094B2 (en) | 2010-01-22 | 2015-06-23 | Ascendis Pharma As | Dipeptide-based prodrug linkers for aliphatic amine-containing drugs |
US20130030359A1 (en) | 2010-01-22 | 2013-01-31 | Ascendis Pharma A/S | Dipeptide-based prodrug linkers for aromatic amine-containing drugs |
US20150335761A1 (en) * | 2012-02-16 | 2015-11-26 | Raymond Firestone | Compositions and methods for contraception |
DK2938360T3 (da) * | 2012-12-28 | 2019-11-25 | Cobiores Nv | Minimalt toksiske prodrugs |
WO2014169697A1 (zh) * | 2013-04-19 | 2014-10-23 | 暨南大学 | 长春碱类衍生物及其制备方法和应用 |
MX2020011946A (es) * | 2013-11-05 | 2022-08-10 | Astrazeneca Ab | Profarmacos de antagonista de (s)-1-fenil-2-(piridin-2-il)etanamin a (nmda). |
JP6744826B2 (ja) | 2014-06-13 | 2020-08-19 | バック バイオサイエンシーズ, エルエルシーBach BioSciences, LLC | Fap活性化治療剤及びそれに関連する使用 |
WO2015192124A1 (en) | 2014-06-13 | 2015-12-17 | Trustees Of Tufts College | Fap-activated therapeutic agents, and uses related thereto |
CN105524141B (zh) * | 2015-11-12 | 2019-11-26 | 中山大学 | 一种FAPa激活式肿瘤诊断多肽磁珠复合物的制备与应用 |
EP3222292A1 (en) | 2016-03-03 | 2017-09-27 | Heidelberg Pharma GmbH | Amanitin conjugates |
CN107043456B (zh) * | 2017-04-19 | 2019-05-17 | 川北医学院 | 对氧环己酮与l-苯丙氨酸氮芥共聚物及其应用 |
CN110128501A (zh) * | 2019-05-21 | 2019-08-16 | 北京海美源医药科技有限公司 | 一种靶向fap酶的喜树碱类化合物及其制备方法和应用 |
CN110128506B (zh) * | 2019-05-22 | 2021-03-30 | 中国药科大学 | 一种寡肽及其应用 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3915800A (en) * | 1972-03-30 | 1975-10-28 | Kelco Co | Polysaccharide and bacterial fermentation process for its preparation |
FR2546163B1 (fr) * | 1983-05-16 | 1987-10-09 | Centre Nat Rech Scient | Nouveaux derives acyles hydrosolubles de peptides ou d'amino-acides, leur preparation et leur application |
US5047401A (en) * | 1985-09-09 | 1991-09-10 | Board Of Regents, The University Of Texas System | Use of dipeptide alkyl esters to treat GVHD |
ES2053547T3 (es) | 1986-07-29 | 1994-08-01 | Sunstar Kk | Reactivo para someter a ensayo enfermedades periodontales. |
US5776892A (en) * | 1990-12-21 | 1998-07-07 | Curative Health Services, Inc. | Anti-inflammatory peptides |
US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
US5866679A (en) | 1994-06-28 | 1999-02-02 | Merck & Co., Inc. | Peptides |
DE19512484A1 (de) * | 1995-04-04 | 1996-10-17 | Bayer Ag | Kohlenhydratmodifizierte Cytostatika |
WO1997014416A1 (en) | 1995-10-18 | 1997-04-24 | Merck & Co., Inc. | Conjugates useful in the treatment of benign prostatic hyperplasia |
CZ389398A3 (cs) | 1996-05-29 | 1999-07-14 | Prototek, Inc. | Proléčiva thalidomidu a jejich použití pro modulaci funkce T-buněk |
US5952294A (en) | 1996-07-31 | 1999-09-14 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Peptidyl prodrugs and methods of making and using the same |
WO1998013059A1 (en) | 1996-09-27 | 1998-04-02 | Bristol-Myers Squibb Company | Hydrolyzable prodrugs for delivery of anticancer drugs to metastatic cells |
DE19640970A1 (de) * | 1996-10-04 | 1998-04-16 | Bayer Ag | Modifizierte Cytostatika |
ATE460180T1 (de) | 1998-12-11 | 2010-03-15 | Coulter Pharm Inc | Prodrugs und verfahren zu deren herstellung |
WO2000064486A2 (en) | 1999-04-28 | 2000-11-02 | Vectramed, Inc. | Enzymatically activated polymeric drug conjugates |
-
2000
- 2000-04-21 US US09/553,800 patent/US6613879B1/en not_active Expired - Lifetime
- 2000-05-11 AU AU65591/00A patent/AU777521B2/en not_active Ceased
- 2000-05-11 EP EP00952966A patent/EP1180116A2/en not_active Withdrawn
- 2000-05-11 JP JP2000619826A patent/JP3607201B2/ja not_active Expired - Fee Related
- 2000-05-11 IL IL14579800A patent/IL145798A0/xx unknown
- 2000-05-11 CZ CZ20014097A patent/CZ20014097A3/cs unknown
- 2000-05-11 HU HU0202367A patent/HUP0202367A3/hu unknown
- 2000-05-11 EE EEP200100600A patent/EE200100600A/xx unknown
- 2000-05-11 BR BR0010564-3A patent/BR0010564A/pt not_active Expired - Fee Related
- 2000-05-11 YU YU80901A patent/YU80901A/sh unknown
- 2000-05-11 CN CNB008075387A patent/CN1213058C/zh not_active Expired - Fee Related
- 2000-05-11 NZ NZ516075A patent/NZ516075A/xx unknown
- 2000-05-11 WO PCT/EP2000/004261 patent/WO2000071571A2/en not_active Application Discontinuation
- 2000-05-11 KR KR1020017014480A patent/KR20020030270A/ko not_active Application Discontinuation
- 2000-05-11 PL PL00351680A patent/PL351680A1/xx not_active Application Discontinuation
- 2000-05-11 SK SK1645-2001A patent/SK16452001A3/sk unknown
- 2000-05-11 CO CO00034117A patent/CO5170516A1/es not_active Application Discontinuation
- 2000-05-11 MX MXPA01011401A patent/MXPA01011401A/es active IP Right Grant
- 2000-05-11 CA CA002369933A patent/CA2369933A1/en not_active Abandoned
- 2000-05-11 EA EA200101155A patent/EA005204B1/ru not_active IP Right Cessation
- 2000-05-12 AR ARP000102287A patent/AR033792A1/es not_active Suspension/Interruption
- 2000-05-12 MY MYPI20002102A patent/MY125939A/en unknown
- 2000-05-12 TW TW089109087A patent/TWI248444B/zh active
- 2000-11-05 UA UA2001128659A patent/UA73506C2/uk unknown
-
2001
- 2001-11-06 ZA ZA200109151A patent/ZA200109151B/en unknown
- 2001-11-09 BG BG106096A patent/BG106096A/bg active Pending
- 2001-11-13 NO NO20015536A patent/NO20015536L/no not_active Application Discontinuation
-
2003
- 2003-02-06 HK HK03100836.5A patent/HK1048642B/zh not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0202367A2 (hu) | FAP-aktivált tumorellenes peptidek, eljárás előállításukra, azokat tartalmazó gyógyszerkészítmények és alkalmazásuk | |
HUP0402458A2 (hu) | Fokozott hatékonyságú kemokin receptor kötő heterociklusos vegyületek | |
HUP0302474A2 (hu) | Terápiásan hatásos tropánszármazékok, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
HUP0303756A2 (hu) | 1-Aril- vagy 1-alkilszulfonil-heterociklobenzazolok és eljárás ezek elõállítására és ezeket tartalmazó gyógyszerkészítmények | |
SE9902987D0 (sv) | Novel compounds | |
HUP9902121A2 (hu) | Gonadotropin-leadó hormon antagonista hatású indolszármazékok és ezeket a vegyületeket tartalmazó gyógyszerkészítmények | |
SE0102438D0 (sv) | New compounds | |
HUP0402360A2 (hu) | Poliaminok alkalmazása progenitor sejtek és/vagy őssejtek számának növelésére alkalmas gyógyszerkészítmény előállítására | |
KR970042553A (ko) | 캠프토테신 유도체 | |
AR037517A1 (es) | Derivados de naftiridinas, un proceso para su preparacion, composicion farmaceutica y el uso de los mismos para la preparacion de un medicamento para el tratamiento de una enfermedad inflamatoria | |
IL127352A (en) | Pyridyl alkene- and pyridyl alkine-acid amides and pharmaceutical compositions containing them | |
HUP0401083A2 (hu) | 4-Amino-6-fenil-pirrolo[2,3-d]pirimidin-származékok, ezeket tartalmazó gyógyászati készítmények és eljárás a vegyületek előállítására | |
UA27100A1 (uk) | Заміщеhі піроли, що мають активhість іhгібіторів протеіhкіhази с, а також їх фармацевтичhо прийhятhі кислотhо-адитивhі солі і фармацевтичhа композиція | |
NO20010995D0 (no) | Cytotoksiske peptider modifisert med store eller lipofile rester | |
ATE254630T1 (de) | Cyclosporine | |
HUP0102579A2 (hu) | Antiangiogén hatású peptid gyógyszervegyületek, azokat tartalmazó gyógyszerkészítmények és alkalmazásuk | |
AR006598A1 (es) | "composiciones anti-fungosas, su uso en la manufactura de medicamentos y un procedimiento para su preparación" | |
HUP0301817A2 (hu) | Kahalalid-vegyületek, elżállításukra szolgáló eljárás, azokat tartalmazó gyógyászati készítmények és alkalmazásuk | |
HUP0002404A2 (hu) | Aminosavszármazékok, hatóanyagként ezeket tartalmazó gyógyszerkészítmények, eljárás előállításukra és alkalmazásuk | |
TW200731975A (en) | Novel combinations of medicaments for the treatment of respiratory diseases | |
HUP0100865A2 (hu) | Meta-azaciklusos csoporttal N-szubsztituált amino-benzoesav-vegyületek és származékaik mint integrin antagonista hatóanyagok, azokat tartalmazó gyógyszerkészítmények és alkalmazásuk | |
TR199802537T2 (xx) | Peptit t�revleri. | |
ES8502417A1 (es) | "un procedimiento para obtener de orina una fraccion que contiene un ingrediente antineoplastico de naturaleza peptidica". | |
HUP0004282A2 (hu) | 2-Halogén-6-0-szubsztituált ketolidszármazékok | |
HUP0002683A2 (hu) | Terápiás anyagok sejtekhez való eljuttatásának fokozására szolgáló készítmények és módszerek |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD9A | Lapse of provisional protection due to non-payment of fees |